Table 2 Ongoing clinical trials evaluating IDCs

PD-L1 (B7-H1)

HLX43

NCT06115642

I

Monotherapy

Pretreated patients

Solid tumors

NCT06848699

Ib/II

In combination with Serplulimab

Pretreated patients

Solid tumors

NCT06839066

II

Monotherapy

Pretreated patients

NPC

NCT06857279

II

Monotherapy

Pretreated patients

HNSCC

NCT06769152

II

Monotherapy

Pretreated patients

Cervical cancer

NCT06769113

II

Monotherapy

Pretreated patients

ESCC

NCT06742892

II

Monotherapy

Pretreated patients

HCC

B7-H3 (CD276)

Ifinatamab deruxtecan

(DS-7300a)

IDeate-PanTumor02 (NCT06330064)

Ib/II

Monotherapy,

Pretreated patients

Endometrial cancer;

HNSCC; pancreatic ductal adenocarcinoma;

CRC; HCC;

adenocarcinoma of esophagus, gastroesophageal junction, and stomach;

urothelial carcinoma;

ovarian cancer;

cervical cancer;

biliary tract cancer;

HER2-low breast cancer;

cutaneous melanoma.

IDeate-Lung02 (NCT06203210)

III

Monotherapy vs standard treatment of physician’s choice,

Pretreated patients

SCLC

IDeate-Lung03 (NCT06362252)

Ib/II

In combination with atezolizumab ± carboplatin,

First-line induction or maintenance

SCLC

IDeate-Esophageal01 (NCT06644781)

III

Monotherapy vs investigator’s choice of chemotherapy,

Pretreated patients

ESCC

KEYMAKER-U01 Substudy 01 A (NCT04165070)

I/II

In combination with pembrolizumab ± carboplatin (part B),

Treatment naïve patients

NSCLC

NCT04471727

I/II

In combination with MK-6070,

Pretreated patients

SCLC

IDeate-Prostate02 (NCT06863272)

I/II

Monotherapy or in combination with MK-5684 or Abiraterone/Enzalutamide,

Pretreated patients

mCRPC

NCT06780137

Ib/II

Monotherapy or in combination with Gacatamig (MK-6070),

Pretreated patients

SCLC

YL201

NCT06241846

II

Monotherapy

Pretreated or non-pretreated patients

mCRPC

NCT06394414

I

In combination with serplulimab with or without platinum-based chemotherapy,

Pretreated or non-pretreated patients

Solid tumors

NCT06612151

III

Monotherapy vs topotecan hydrochloride

Pretreated patients

SCLC

NCT06629597

III

Monotherapy vs

investigator’s choice of chemotherapy,

Pretreated patients

NPC

HS-20093

ARTEMIS-003

(NCT06001255)

II

Monotherapy

Pretreated patients

mCRPC and other solid tumors

ARTEMIS-005 (NCT06112704)

II

Monotherapy

Pretreated patients

Esophageal carcinoma or other advanced solid tumors

ARTEMIS-006

(NCT06007729)

II

Monotherapy

Pretreated patients

HNSCC and other solid tumors

ARTEMIS-007

(NCT06052423)

II (Withdrawn due to

research and development strategy adjustment)

Monotherapy

Non-pretreated patients

SCLC

ARTEMIS-008

(NCT06498479)

III

Monotherapy vs topotecan

Pretreated patients

SCLC

ARTEMIS-009 (NCT06526624)

III

Monotherapy as consolidation therapy vs active surveillance

Limited stage SCLC

ARTEMIS-101

(NCT06332170)

I

In combination with Adebrelimab or cetuximab or Enzalutamide

± Platinum-containing chemotherapy

Pretreated or non-pretreated patients

Solid tumors

ARTEMIS-103

(NCT06699576)

Ib

In combination with adebrelimab or anlotinib and/or epirubicin,

Pretreated patients

Bone and Soft Tissue Sarcoma

ARTEMIS-102

(NCT06825624)

Ib

In combination with bevacizumab and capecitabine or 5-fluorouracil or 5-fluorouracil and oxaliplatin,

Pretreated or non-pretreated patients

CRC

NCT06621563

Ib

In combination with HS-20117 ± Platinum-containing chemotherapy

Pretreated patients

Solid tumors

NCT06551142

I

Monotherapy or in combination with platinum or atezolizumab or pembrolizumab or durvalumab or cetuximab or bevacizumab

Pretreated patients

Solid tumors

NCT06885034

Ib/II

Monotherapy

Pretreated patients

CRC

NCT05277051

I

Monotherapy or in combination with dostarlimab and/or belrestotug ± nelistotug

Pretreated patients

HNSCC, NSCLC, RCC, breast cancer, gastric cancer, CRC, endometrial cancer, ovarian cancer

Vobramitamab duocarmazine

(MGC018)

NCT05293496

I

In combination with MGD019/lorigerlimab

Pretreated patients

Solid tumors

NCT06227546

II

Monotherapy

Pretreated patients

SCLC

MHB088C

NCT05652855

I/II

Monotherapy

Pretreated patients

Solid tumors

ILB-3101

NCT06426680

I/II

Monotherapy

Pretreated patients

Solid tumors

MGC026

NCT06242470

I/II

Monotherapy

Pretreated patients

Solid tumors

IBI3001

NCT06349408

I/II

Monotherapy

Pretreated patients

Solid tumors

BAT8009

NCT05405621

I

Monotherapy

Pretreated patients

Solid tumors

7MW3711

NCT06008379

I/II

Monotherapy

Pretreated patients

Solid tumors

NCT06008366

I/II

Monotherapy

Pretreated patients

Solid tumors

IBI129

NCT05991349

I/II

Monotherapy

Pretreated patients

Solid tumors

BGB-C354

NCT06422520

I

Monotherapy or in combination with tislelizumab

Pretreated patients

Solid tumors

SKB500

NCT06736327

I

Monotherapy

Pretreated patients

Solid tumors

B7-H4

HS-20089

NCT06014190

II

Monotherapy

Pretreated patients

Ovarian and endometrial cancer

NCT06336707

I

In combination with adebrelimab ± platinum or bevacizumab ± platinum

Pretreated patients

Solid tumors

NCT06855069

III

Monotherapy vs investigator’s choice of chemotherapy,

Pretreated patients

Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Emiltatug Ledadotin

(XMT-1660)

NCT05377996

I

Monotherapy

Pretreated patients

Breast, endometrial, and ovarian cancer

BG-C9074

NCT06233942

I

Monotherapy and in combination with tislelizumab

Pretreated patients

Solid tumors

LNCB74

NCT06774963

I

Monotherapy

Pretreated patients

Solid tumors

CD56

DXC006

NCT06224855

I

Monotherapy

Pretreated patients

Solid and hematologic tumors

CD70

PRO-1160

NCT05721222

I

Monotherapy

Pretreated patients

RCC, NPC, non-Hodgkin lymphoma

CD73

BB-1709

NCT06241898

I

Monotherapy

Pretreated patients

Solid tumors